Northern Trust’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Northern Trust’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,222	Closed	-$3.64K	–	4639
2023 Q1	$3.64K	Hold	1,222	–	–	﹤0.01%	4568
2022 Q4	$6.11K	Hold	1,222	–	–	﹤0.01%	4619
2022 Q3	$8K	Hold	1,222	–	–	﹤0.01%	4658
2022 Q2	$9K	Sell	1,222 -3,348	-73%	-$30.5K	﹤0.01%	4705
2022 Q1	$67K	Sell	4,570 -31	-0.7%	-$788	﹤0.01%	4462
2021 Q4	$221K	Sell	4,601 -67	-1%	-$7.04K	﹤0.01%	4167
2021 Q3	$682K	Sell	4,668 -2,724	-37%	-$354K	﹤0.01%	3664
2021 Q2	$855K	Sell	7,392 -44	-0.6%	-$4.91K	﹤0.01%	3559
2021 Q1	$716K	Buy	+7,436	New	+$970K	﹤0.01%	3709

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust's LABP Position: Q2 2023 in Review

Northern Trust sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2023, closing a stake of 1,222 shares — an estimated $3.64K sold.

Northern Trust first reported a position in LABP in Q1 2021 and held it in 9 quarters. The position peaked at $855K in Q2 2021. 8 funds tracked by Wall St. Rank hold LABP as of Q2 2023.

Northern Trust reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Northern Trust sold 1,222 Landos Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $3.64K.
Northern Trust first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Northern Trust's Landos Biopharma, Inc. Common Stock position peaked at $855K in Q2 2021.
8 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2023.

Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.